Eyal C. Attar Aprea Therapeutics, Inc. (APRE) insider trading activity

Eyal C. Attar is SVP, Chief Medical Officer of Aprea Therapeutics, Inc.. Currently has a direct ownership of 57,233 shares of APRE, which is worth approximately $218,630. The most recent transaction as insider was on Jun 03, 2022, when has been sold 32,667 shares (Common Stock) at a price of $0.8 per share, resulting in proceeds of $26,134. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 57.2K

0% 3M change

0% 12M change

Total Value Held $218,630

Eyal C. Attar Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 03 2022	SELL Payment of exercise price or tax liability	$26,134 $0.8 p/Share	32,667 Reduced 36.34%	57,233 Common Stock
Mar 10 2022	BUY Grant, award, or other acquisition	-	42,900 Added 32.3%	89,900 Common Stock
Feb 28 2022	SELL Open market or private sale	$62,280 $1.73 p/Share	36,000 Reduced 43.37%	47,000 Common Stock
Sep 16 2021	SELL Open market or private sale	$74,730 $4.68 p/Share	15,968 Reduced 16.13%	83,000 Common Stock
Aug 25 2021	SELL Payment of exercise price or tax liability	$35,947 $3.98 p/Share	9,032 Reduced 8.36%	98,968 Common Stock
Feb 25 2021	BUY Grant, award, or other acquisition	-	108,000 Added 50.0%	108,000 Common Stock

Also insider at

VOR

Vor Biopharma Inc. Healthcare

CHIEF MEDICAL OFFICER

ECA

Eyal C. Attar

SVP, Chief Medical Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APRE shares.

Notify only if

Value

Insider Trading

Get notified when an Aprea Therapeutics, Inc. insider buys or sells APRE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aprea Therapeutics, Inc.

Track Activities on APRE

Account